IP Library Granted Patent US 9,498,195
Granted Patent B2
US 9,498,195 · App. 14/088,904 · Granted Nov 22, 2016

Implant with high vapor pressure medium

Inventors: Ernest G. Schutt (San Diego, CA); Kevin G. Connors (Wellesley, MA); John Gillespie, Jr. (Dover, MA); Peter Dayton (Brookline, MA)
Assignee: AttenueX Technologies, Inc.
A61B17/00234A61B17/0401A61B17/221A61B17/3468A61B17/66A61B17/70A61B17/7065A61B17/82A61B90/02A61F2/004A61F2/0027A61F2/12A61F2/2481A61F2/26A61M25/00A61M25/10A61M29/02A61B1/307A61B5/205A61B17/32056A61B17/3478A61B17/7098A61B18/1442A61B2017/00539A61B2017/00557A61B2017/00858A61B2017/0435A61B2017/2215A61B2017/22035A61B2017/22062A61F2/0059A61F2/042A61F2/10A61F5/0013A61F9/00781A61F13/20A61F13/26A61F2002/3071A61F2002/30617A61F2250/0059A61F2250/0067A61F2250/0068A61F2250/0085A61F2250/0097A61M25/04A61M25/1002A61M2025/0076A61M2025/1054A61M2210/1078A61M2210/1085
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,498,195
App. No.
14/088,904
Granted
Nov 22, 2016
Kind
B2
Abstract

An implant for use in a human or animal body can include a flexible housing with an outer wall and having a chamber therein. The implant can have at least one high vapor pressure medium within the chamber. The at least one high vapor pressure medium can have a combined vapor pressure equal to or greater than about the average value of the hydrostatic pressure of the implantation site plus the skin tension of the housing minus the gas tension of the dissolved gasses present at the implantation site.

Claims (12)

1. A method of treating urinary incontinence in a human or animal body comprising:

ensuring at least 100 cc of liquid or gas is within a bladder prior to implantation;

implanting an inflatable implant within the bladder, the inflatable implant device comprising a flexible housing comprising an outer wall defining a chamber;

injecting into the chamber, while within the bladder, at least one high vapor pressure medium within the chamber having a vapor pressure equal to or greater than P anatomical environment/hydrostatic-avg +P Skin-tension −P Dissolved gas in absolute pressure, wherein the one or more high vapor pressure medium comprises a vapor and a reservoir of liquid; and

vaporizing, while within the body, at least some of the liquid as the vapor leaves the chamber, thereby the vaporizing maintains the implant in an inflated state for the duration of a treatment period of at least 5 days.

2. The method of claim 1 , wherein injecting into the chamber further comprises injecting the at least one high vapor pressure medium with a vapor pressure between about 100-150 cm H 2 O.

3. The method of claim 1 , further comprising one of increasing or decreasing the pressure within the flexible housing over the treatment period via transport of molecules across the outer wall after implanting the inflatable implant.

4. The method of claim 1 , further comprising one of increasing or decreasing a volume of the flexible housing over the treatment period via transport of molecules across the outer wall after implanting the inflatable implant.

5. The method of claim 1 , wherein the duration of a treatment period is at least 90 days and vaporizing further comprises maintaining the implant in an inflated state for at least 90 days.

6. The method of claim 1 , wherein the outer wall is made of a gas permeable material that allows permeation of the at least one high vapor pressure medium at a rate of at least 15 ml per twelve months out of the implant.

7. The method of claim 1 , further comprising ensuring at least 200 cc of liquid or gas is within the bladder prior to implantation.

8. The method of claim 1 , wherein implanting the inflatable implant comprises implanting the inflatable implant transurethrally into a bladder.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: ATTENUEX TECHNOLOGIES, INC.
To: SOLACE THERAPEUTICS, INC.
Reel/Frame 049282/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: GILLESPIE, JOHN, JR.; CONNORS, KEVIN G.; DAYTON, PETER; SCHUTT, ERNEST G.
To: ATTENUEX TECHNOLOGIES, INC.
Reel/Frame 040035/0388 →
Continuity (5)
Continuation 13925659 · Jun 24, 2013
Continuation 12625508 · Nov 24, 2009
Provisional Application 61200147 · Nov 25, 2008
Provisional Application 61211515 · Mar 31, 2009
Related Publication 20140081076A1 · Mar 20, 2014